XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables)
3 Months Ended
Mar. 31, 2023
Investments, All Other Investments [Abstract]  
SCHEDULE OF FAIR VALUE MEASUREMENT ON RECURRING BASIS

The following fair value hierarchy table present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2023:

 

   Fair Value Measurement as of March 31, 2023 
   (In thousands) 
   Level 1   Level 2   Level 3   Balance 
Warrant liability  $      -   $     -   $1,333   $1,333 
Total  $-   $-   $1,333   $1,333 
SCHEDULE OF FAIR VALUE LIABILITIES ON RECURRING BASIS

The following table represent a reconciliation of the Company’s liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2023:

 

   Warrant Liability 
   (In thousands) 
     
Beginning balance, January 1  $- 
Issuance of warrants   14,453 
Exercise of warrants   (2,847)
Change in fair value upon re-measurement   (10,273)
Ending balance, March 31  $1,333 
SCHEDULE OF FAIR VALUE PRICING MODEL

The Company has re-measured the liability to estimate fair value at March 31, 2023, using the Black-Scholes option pricing model with the following assumptions:

 SCHEDULE OF FAIR VALUE PRICING MODEL

   January 9,
2023
   March 31,
2023
 
         
Measurement date closing price of Common Stock (1)  $1.44   $0.34 
Contractual term (years) (2)   5.5    5.3 
Risk-free interest rate   3.6%   3.5%
Volatility   100%   100%
Dividend yield   0%   0%

 

 

  (1) Based on the trading value of common stock of Vivos Therapeutics, Inc. as of January 9, 2023 and each presented period ending date.
     
  (2) The valuation of warrants is based on the contractual term of the warrant rather than the expected term.